Fatal lupus-like syndrome and ARDS induced by fluvastatin

Sridhar, M.; Abdulla, A.

doi:10.1016/s0140-6736(98)85019-8

Cited by 36 publications

(13 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Statins have also been implicated in a few cases of lupus-like syndromes and dermatomyositis [1, 2, 3]. A lethal outcome has been observed in 1 case [4]. We present a new case which supports that statins can also trigger systemic autoimmune reactions.…”

Section: Introductionsupporting

confidence: 51%

Lupus-Like Syndrome Associated with Statin Therapy

Noël

Panizzon²

2004

Dermatology

View full text Add to dashboard Cite

Statins are among the most widely prescribed drugs. An increasing number of lupus-like syndrome has recently been reported with these lipid-lowering agents. We describe a new case associated with simvastatin therapy. The presence of anti-dsDNA antibodies in the serum is for the first time reported confirming that statins may also induce a systemic autoimmune reaction. Statin-induced lupus-like syndrome is characterized by the long delay between the beginning of therapy and the skin eruption. Antinuclear antibodies may persist for many months after drug discontinuation. The causal relationship may be therefore difficult to establish, and probably many cases are unrecognized. Early diagnosis may avoid unnecessary immunosuppressive therapy.

show abstract

Section: Introductionsupporting

confidence: 51%

Lupus-Like Syndrome Associated with Statin Therapy

Noël

Panizzon²

2004

Dermatology

View full text Add to dashboard Cite

show abstract

“…In most cases, ANAs were still positive many months after cessation of the offending drug despite clinical recovery. A fatal case due to acute respiratory distress syndrome has been reported despite high doses of systemic corticosteroids and cyclophosphamide 7 . One patient had persisting disease despite drug withdrawal and immunosuppressive therapy 5 .…”

Section: Resultsmentioning

confidence: 99%

“…Thirteen cases of statin-induced LE have been reported ( Table 2). [2][3][4][5][6][7][8][9][10][11][12] Ten cases were considered as drug-induced systemic lupus erythematosus (SLE) and three cases as drug-induced SCLE. All were positive for antinuclear antibodies (ANA).…”

Section: Resultsmentioning

confidence: 99%

Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review

Noël¹

2006

Acad Dermatol Venereol

138

View full text Add to dashboard Cite

show abstract

“…[358,693] A later study attributed the lesser benefit of the more potent atorvastatin to selective benefits by simvastatin -the less potent statin in that study (vs alternatives explanations such as atorvastatin more effectively overcoming benefits of high LDL-C). Associations of higher lipid levels to conditions [685] may reflect protective adaptations rather than causal predispositions See in-depth discussion of proposed mechanism for statin-associated neurodegeneration [146] Immune, -Case series and reports of lupus-like syndrome, -Cholesterol is the precursor to vitamin D. High levels of vitamin D autoimmune c autoimmune hepatitis, dermatomyositis, and are associated with lower autoimmune disease risk, which we propose other [67,71,72,74,475,499,503,504,507,[700][701][702][703][704][705][706][707][708][709][710][711][712][713][714][715][716] as a possible mechanism [717][718][719][720][721][722][723][724][725][726][727][728][729] -See above (table I) for case reports of Guillain -Enthusiasm for trials ...…”

Section: Continued Next Pagementioning

confidence: 99%

Statin Adverse Effects

Golomb

Evans

2008

American Journal of Cardiovascular Drugs

592

257

View full text Add to dashboard Cite

HMG-CoA reductase inhibitors (statins) are a widely used class of drug, and like all medications, have potential for adverse effects (AEs). Here we review the statin AE literature, first focusing on muscle AEs as the most reported problem both in the literature and by patients. Evidence regarding the statin muscle AE mechanism, dose effect, drug interactions, and genetic predisposition is examined. We hypothesize, and provide evidence, that the demonstrated mitochondrial mechanisms for muscle AEs have implications to other nonmuscle AEs in patients treated with statins. In meta-analyses of randomized controlled trials (RCTs), muscle AEs are more frequent with statins than with placebo. A number of manifestations of muscle AEs have been reported, with rhabdomyolysis the most feared. AEs are dose dependent, and risk is amplified by drug interactions that functionally increase statin potency, often through inhibition of the cytochrome P450 3A4 system. An array of additional risk factors for statin AEs are those that amplify (or reflect) mitochondrial or metabolic vulnerability, such as metabolic syndrome factors, thyroid disease, and genetic mutations linked to mitochondrial dysfunction. Converging evidence supports a mitochondrial foundation for muscle AEs associated with statins, and both theoretical and empirical considerations suggest that mitochondrial dysfunction may also underlie many nonmuscle statin AEs. Evidence from RCTs and studies of other designs indicates existence of additional statin-associated AEs, such as cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction. Physician awareness of statin AEs is reportedly low even for the AEs most widely reported by patients. Awareness and vigilance for AEs should be maintained to enable informed treatment decisions, treatment modification if appropriate, improved quality of patient care, and reduced patient morbidity.

show abstract

Fatal lupus-like syndrome and ARDS induced by fluvastatin

Cited by 36 publications

References 3 publications

Lupus-Like Syndrome Associated with Statin Therapy

Lupus-Like Syndrome Associated with Statin Therapy

Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review

Statin Adverse Effects

Contact Info

Product

Resources

About